Is that something likely to happen? I think the company will be looking forward to delivering their EOY P&L, it's likely to look really strong, exceeding all budget expectations. To date their sales are great and their margin GP is great as well. Add to that their recent deal with Priceline and they now have the expanded platform to expose more product to more people.
That's without even talking about their commitment to clinical based supplements that actually work. Again, their approach to medicine is really exciting.
These views are my own of course.
One step forward Two steps backwards, page-2
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BIO (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
67.0¢ |
Change
0.060(9.84%) |
Mkt cap ! $146.8M | |||
| Open | High | Low | Value | Volume |
| 64.0¢ | 69.0¢ | 64.0¢ | $608.9K | 915.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 441 | 67.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 67.5¢ | 9000 | 1 |
View Market Depth
| Last trade - 16.10pm 13/11/2024 (20 minute delay) ? |
| BIO (ASX) Chart |